🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05562622
Active, not recruiting Not applicable

Assessment of DOT Spectacles in Chinese Children

NCT05562622 · tracked via the Priya Life Science China tracker
Sponsor
SightGlass Vision, Inc.
Phase
Not applicable
Started
2023-02-05
Last updated
2026-07-13

Condition(s) studied

Juvenile MyopiaMyopia

Investigational drug(s) / intervention(s)

Novel spectacle lens designSpectacle lenses

Novel spectacle lens design: Use of lenses may reduce the rate of progression of juvenile myopia

Spectacle lenses: Use of lenses may reduce the rate of progression of juvenile myopia

Study summary

This is a randomized, controlled, evaluator-blinded, multicenter, two-arm parallel group clinical trial to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses by comparing to single vision, impact-resistant spectacle lenses in reducing the progression of myopia in children of Chinese origin.

Eligibility

Sex
ALL
Min age
6 Years
Max age
13 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Children 6-13 years of age 2. SER error between -0.75D and -5.00D 3. Willingness to wear study spectacles and participate in the trial for 12 months without contact lens wear Exclusion Criteria: 1. Prior usage of atropine, multifocal contact lenses, or orthokeratology (ortho-K) 2. Astigmatism worse than -1.50 DC (by manifest refraction) in either eye 3. Anisometropia (SER manifest refraction) greater than 1.00 D

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Aier Eye Hospital Changsha China
West China Hospital Chengdu China
Zhongshan Ophthalmic Center Guangzhou China
Fudan University EENT Shanghai China
Tianjin Eye Hospital Tianjin China

More SightGlass Vision, Inc. trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05562622 on ClinicalTrials.gov ↗ ← All trials in China